제품 수집
제품 세부정보
Synonyms
TNFRSF9, 4-1BB, CD137, CDw137, ILA
Source
Biotinylated Human 4-1BB, Fc,Avitag (41B-H82F8) is expressed from human 293 cells (HEK293). It contains AA Leu 24 - Gln 186 (Accession # Q07011-1).
Predicted N-terminus: Leu 24
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 45.4 kDa. The protein migrates as 55-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Labeling
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Protein Ratio
Passed as determined by the SABA assay / HABA assay / binding ELISA.
Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
고객님도 확인한 상품
데이터 표시
SDS-PAGE
Biotinylated Human 4-1BB, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
SEC-MALS
The purity of Biotinylated Human 4-1BB, Fc,Avitag (Cat. No. 41B-H82F8) is more than 95% and the molecular weight of this protein is around 98-120 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Biotinylated Human 4-1BB, Fc,Avitag (Cat. No. 41B-H82F8) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind UreluMab, Human IgG4 with a linear range of 0.1-6 ng/mL (QC tested).
Protocol
Immobilized Human 4-1BB Ligand, Mouse IgG2a Fc Tag, low endotoxin at 2 μg/mL (100 μL/well) can bind Biotinylated Human 4-1BB, Fc,Avitag (Cat. No. 41B-H82F8) with a linear range of 0.2-3 ng/mL (Routinely tested).
Protocol
Bioactivity-Flow Cytometry
FACS assay shows that Biotinylated Human 4-1BB, Fc,Avitag (41B-H82F8) can bind to HEK293/Human 4-1BB Ligand / TNFSF9 Stable Cell Line (CHEK-ATP039). The concentration of Biotinylated Human 4-1BB, Fc,Avitag (41B-H82F8) used is 10 μg/mL (Routinely tested).
Protocol
사용자 리뷰 댓글 남기기
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
배경 소개
프론티어 진행
의약품 개발 진행- 영어 이름：
Tumor necrosis factor receptor superfamily member 9
- 카테고리：
- 상장 의약품 수：
0 상세
- 임상 의약품 수：
77 상세
- 최고 개발 단계：
Phase 3 Clinical
연락하기
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
신약 후보물질 라이선싱
